Monash University announced today the grant of an exclusive licence of its portfolio of proprietary synthetic polymyxin antibiotics to Qpex Biopharma, a US-based biopharmaceutical company focused on developing new antibiotics to combat the
Collaboration will use technology licensed to PureTech Health to develop Boehringer Ingelheim’s novel immuno-oncology product candidates
The Monash Institute of Pharmaceutical Sciences has again received excellent results in the latest Excellence in Research for Australia (ERA) rankings.
Breakthrough research at Monash University has shown how different areas of major diabetes and obesity drug targets can be ‘activated’, guiding future drug development and better treatment of diseases.Medicine & health
Drug discovery research at Monash has underpinned a new spin out company to develop therapies for metabolic syndrome and type-2 diabetes-related diseases.Medicine & health
Chronic obstructive pulmonary disease (COPD) is the fifth leading cause of death in Australia, with 7.5% of Australians over the age of 40 years experiencing moderate to severe forms of the disease. Smoking is the main cause of COPD, with as many
The Monash Faculty of Pharmacy and Pharmaceutical Sciences has been awarded nearly $20 million dollars in research funding in the recent rounds of grants announced by the National Health and Medical Research Council (“NHMRC”) and the
Three researchers from the Drug Discovery Biology theme at the Monash Institute of Pharmaceutical Sciences have received prestigious awards from the British Pharmacological Society.
Dr Lauren May, of the Drug Discovery Biology research theme at the Monash Institute of Pharmaceutical Science, has received a Heart Foundation Future Leaders Fellowship and Paul Korner Innovation Award.